Qiagen N.V. (ETR:QIA)
Germany · Delayed Price · Currency is EUR | Market Cap | 7.60B -13.3% |
| Revenue (ttm) | 1.82B +4.8% |
| Net Income | 348.80M +329.3% |
| EPS | 1.68 +338.2% |
| Shares Out | n/a |
| PE Ratio | 21.78 |
| Forward PE | 16.69 |
| Dividend | 2.27 (6.60%) |
| Ex-Dividend Date | Jul 7, 2026 |
| Volume | 1,975,681 |
| Open | 32.82 |
| Previous Close | 33.15 |
| Day's Range | 32.82 - 37.87 |
| 52-Week Range | 27.56 - 47.60 |
| Beta | 0.66 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 3, 2026 |
About Qiagen
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purif... [Read more]
Financial Performance
In 2025, Qiagen's revenue was $2.09 billion, an increase of 5.65% compared to the previous year's $1.98 billion. Earnings were $424.88 million, an increase of 408.28%.
Financial numbers in USD Financial StatementsNews
Qiagen gains after report of early PE interest including EQT, Advent
Shares of Qiagen (QGEN) are trading higher after following reports that the European molecular testing company has drawn early takeover interest from firms including EQT AB (EQBBF) and Advent. KKR…
Qiagen draws early takeover interest from EQT, Advent & KKR, Bloomberg News reports
Qiagen is drawing early takeover interest from buyout firms, including EQT AB , Advent and KKR , Bloomberg News said on Thursday, citing people familiar with the matter.
Qiagen drawing takeover interest from Advent, EQT, Bloomberg reports
According to the report, some of Qiagen’s (QGEN) suitors are considering offering at least $50 per share.
Qiagen initiated with a Hold at Kepler Cheuvreux
Kepler Cheuvreux initiated coverage of Qiagen (QGEN) with a Hold rating and $38.60 price target The firm views the company as a “solid franchise,” citing its greater exposure to life…
Qiagen Transcript: AGM 2026
The AGM highlighted strong 2025 financial results, a 40% dividend increase, and board renewal. Shareholders approved all proposals, including share buybacks and auditor reappointment, while management addressed questions on capital allocation and strategic direction.
Qiagen Slides: FY 2026
Qiagen has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 24, 2026.
Qiagen upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Qiagen (QGEN) to Overweight from Equal Weight with a price target of $42, up from $40. The firm says signs of a growth inflection coupled with sector…
Qiagen Transcript: Investor update
QIAcuity digital PCR is driving rapid growth in the molecular testing market with its integrated, scalable, and user-friendly platform, capturing significant market share and enabling high-sensitivity applications across research, clinical, and pharma sectors. Strategic investments target gene expression, companion diagnostics, and new product launches to sustain double-digit growth.
Qiagen Slides: Investor update
Qiagen has posted slides in relation to its latest quarterly earnings report, which was published on June 15, 2026.
QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma
VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its QIAcuity digital PCR (dPCR) ecosys...
Qiagen Transcript: Jefferies Global Healthcare Conference 2026
Q1 results were mixed, with QuantiFERON impacted by U.S. immigration changes and Middle East instability, but other growth drivers and pharma performed well. New product launches and automation partnerships are expected to drive H2 growth, while margin expansion remains a focus despite near-term headwinds.
Qiagen Slides: FY 2026
Qiagen has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 3, 2026.
QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak
VENLO, Netherlands, & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the availability of two custom-designed research-use-o...
QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows
VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the global launch of QIA Agent, an AI-powered digital a...
Qiagen Digital Insights to integrate Nvidia accelerated computing
Qiagen (QGEN) announced at the 2026 BIO-IT World Conference & Expo in Boston that the Qiagen Digital Insights bioinformatics business and its curated knowledge bases and bioinformatics expertise will ...
QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA
VENLO, Netherlands & REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced at the 2026 BIO-IT World Conference & Expo in Boston that the...
Qiagen price target lowered to $36 from $50 at Stifel
Stifel lowered the firm’s price target on Qiagen (QGEN) to $36 from $50 and keeps a Hold rating on the shares citing a lower growth outlook after the company started…
Qiagen Transcript: Bank of America Global Healthcare Conference 2026
Board changes and a CEO search are underway, with new share buybacks and a 40% dividend increase proposed. Guidance was revised due to a drop in U.S. immigration-related QuantiFERON sales, but other growth pillars and new product launches are on track. Operating margin targets and midterm growth goals remain intact.
Qiagen Slides: FY 2026
Qiagen has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 12, 2026.
QIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General Meeting
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced proposals for its 2026 Annual General Meeting, including plans to appoint co-f...
Qiagen price target lowered to $40 from $46 at TD Cowen
TD Cowen analyst Dan Brennan lowered the firm’s price target on Qiagen (QGEN) to $40 from $46 and keeps a Hold rating on the shares. The firm updated its model…
Qiagen Transcript: Status update
Latent TB testing is a rapidly growing market with significant conversion potential from traditional skin tests. New innovations include faster, fully automated workflows and an AI tool for risk stratification, all exclusive to QuantiFERON. Customer feedback is strong, and the company remains confident in its 2028 financial targets.
Qiagen Slides: Status update
Qiagen has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Qiagen Slides: Investor presentation
Qiagen has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
QIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB Testing
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to advance its QuantiFERON latent tuberculosis (TB) test with a new...